Blood markers for predicting outcomes in myelodysplastic syndromes
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether certain blood test results can help predict how myelodysplastic syndromes (MDS) will progress. It may help doctors better understand your condition and plan your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with myelodysplastic syndromes (MDS).
- Your medical records include blood test results for hemoglobin, albumin, lymphocytes, platelets, monocytes, fibrinogen, and liver enzymes (AST and ALT).
- You have been followed by your doctor for at least 12 months after diagnosis, or until death.
- You do not have active infections, liver cirrhosis, chronic inflammatory diseases, or other cancers at the time of diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
This study is looking at how a certain biological pathway (called BMP) affects the progression of blood cancers like MDS and AML. By understanding this, doctors hope to find better ways to predict or treat these conditions.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study looks at whether certain signs of inflammation in the blood can help predict heart problems in people with myelodysplastic syndromes (MDS). If you have MDS and are generally well enough to participate, this trial may help doctors better understand and manage your risk of heart disease.
Hear when a new Myelo Dysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.